(R)-tert-butyl 3-((S)-1-(3-bromophenyl)-1-hydroxy-5-methoxy-pentyl)piperidine-1-carboxylate | 884514-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (R)-tert-butyl 3-((S)-1-(3-bromophenyl)-1-hydroxy-5-methoxy-pentyl)piperidine-1-carboxylate
• 英文别名: tert-butyl (3R)-3-[(1S)-1-(3-bromophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxylate
• CAS: 884514-17-4
• 化学式: C₂₂H₃₄BrNO₄
• 分子量: 456.42
• InChiKey: FGFFORZHOJEWFE-XMSQKQJNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 3-((S)-1-(3-bromophenyl)-1-hydroxy-5-methoxy-pentyl)piperidine-1-carboxylate 在 盐酸 、 水 作用下， 以 乙腈 为溶剂， 生成 (1S)-1-(3-bromophenyl)-5-methoxy-1-[(3R)-piperidin-3-yl]pentan-1-ol
  参考文献：
  名称：

  Design and optimization of renin inhibitors: Orally bioavailable alkyl amines

  摘要：

  Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47 nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.140
• 作为产物：
  描述：

  tert-butyl (R)-3-(3-bromobenzoyl)piperidine-1-carboxylate 、 magnesium,1-methoxybutane,chloride 以 四氢呋喃 为溶剂， 生成 (R)-tert-butyl 3-((S)-1-(3-bromophenyl)-1-hydroxy-5-methoxy-pentyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Design and optimization of renin inhibitors: Orally bioavailable alkyl amines

  摘要：

  Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47 nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.140

文献信息

• Diaminoalkane Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20090018103A1

  公开（公告）日：2009-01-15

  Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.

  公式I的Diaminoalkanes现已被发现，它们具有口服活性并结合到天冬氨酸蛋白酶以抑制其活性。它们在治疗或改善与天冬氨酸蛋白酶活性升高相关的疾病方面非常有用。本发明还涉及使用公式I化合物治疗或改善需要的天冬氨酸蛋白酶相关疾病的方法，包括向该受体施用公式I化合物的有效量。
• Diaminoalkane aspartic protease inhibitors
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：US07754737B2

  公开（公告）日：2010-07-13

  Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.

  已经发现了具有公式I的二氨基烷，其口服活性并结合天冬氨酸蛋白酶以抑制其活性。它们在治疗或改善与天冬氨酸蛋白酶活性升高相关的疾病方面是有用的。本发明还涉及一种使用公式I的化合物改善或治疗需要该方案的主体中的天冬氨酸蛋白酶相关疾病的方法，包括向该主体施用公式I的化合物的有效量。
• US7754737B2
  申请人：——

  公开号：US7754737B2

  公开（公告）日：2010-07-13
• US8455521B2
  申请人：——

  公开号：US8455521B2

  公开（公告）日：2013-06-04
• [EN] DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS<br/>[FR] DIAMINOALCANE INHIBITEURS DE LA PROTEASE ASPARTIQUE
  申请人：VITAE PHARMACEUTICAL INC

  公开号：WO2006042150A1

  公开（公告）日：2006-04-20

  Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.